In-vivo B-cell activity predicts response to treatment with glatiramer acetate and interferons in patients with relapsing-remitting multiple sclerosis (RRMS)

Braune S, Tacke S, Ziemssen T, Lehmann P, Bergmann A, Kürten S (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Neurology American Academy of Neurology (AAN)

Publisher: LIPPINCOTT WILLIAMS & WILKINS

City/Town: PHILADELPHIA

Conference Proceedings Title: NEUROLOGY

Event location: Toronto, CANADA

Authors with CRIS profile

Sabine Tacke Lehrstuhl für Mikroskopische Anatomie und Molekulare Zellbiologie Stefanie Kürten Lehrstuhl für Mikroskopische Anatomie und Molekulare Zellbiologie

Involved external institutions

Case Western Reserve University US United States (USA) (US) Universitätsklinikum Carl Gustav Carus Dresden DE Germany (DE) NeuroTransData GmbH DE Germany (DE)

How to cite

APA:

Braune, S., Tacke, S., Ziemssen, T., Lehmann, P., Bergmann, A., & Kürten, S. (2020). In-vivo B-cell activity predicts response to treatment with glatiramer acetate and interferons in patients with relapsing-remitting multiple sclerosis (RRMS). In NEUROLOGY. Toronto, CANADA: PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

MLA:

Braune, Stefan, et al. "In-vivo B-cell activity predicts response to treatment with glatiramer acetate and interferons in patients with relapsing-remitting multiple sclerosis (RRMS)." Proceedings of the Annual Meeting of the American-Academy-of-Neurology, Toronto, CANADA PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2020.

BibTeX: Download